REVERE DATATM RELEASES UPDATED BIOTECH PIPELINE RISK REPORT

Report Highlights Lower-Risk Companies with Promising Pipelines and Strong Partners

New York, September 26, 2005 – Revere Data™ LLC, a fast-growing provider of independent research data and investment analytics, today announced a newly updated Biotech Pipeline Risk Report that identifies micro- to mid-cap biotechnology companies with promising but relatively low-risk drug development
pipelines.

The Biotech Pipeline Risk Report is designed to generate ideas for trading and investment opportunities in the Biopharmaceuticals sector. The updated Report is available on Revere Data’s website.

Specifically, the Biotech Pipeline Risk Report identifies companies that meet all of the following criteria:

1. At least two Phase III or FDA-filed drug candidates
2. One or more drug candidates utilizing a mechanism of action already approved by the FDA in other
drugs
3. One or more drug candidates facing two or fewer alternative drugs with the same mechanism of
action for the same indication
4. An established strategic partnership with at least one blue-chip biopharmaceutical company
5. Market capitalization between $50 million and $1 billion

"The 16 Biotech companies profiled in the February 17, 2005 Biotech Pipeline Risk Report provided evidence that companies meeting the stringent report requirements demonstrated less volatility than Biotech companies with only one late stage drug in their pipeline," said Brian Hill, Director of Research for Revere Data. "5 out of the 16 featured companies had negative clinical results or FDA decisions in the past 6 months, dropping an average of 24.9%. Biotech companies dependent on single late stage drugs dropped an average of 51.9% over the same period after receiving negative results".

"Clearly pipeline diversification is key to risk management and successful Biotech investing. Revere Data is uniquely positioned to offer unparalleled visibility into the pipeline risks and opportunities of all publicly
traded Biotech companies" said Glen Wolyner, Chief Executive Officer of Revere Data.

Revere Data offers clients the flexibility to access its exclusive content through Revere Research, a userfriendly web based platform or Revere Datafeed, data files that can be integrated into research and trading applications as well as algorithms. With either application, users gain access to Revere Data’s intelligent database of U.S publicly traded companies and ADR's not available through other research providers. Revere Data’s clientele includes sellside agency and proprietary traders, buyside traders, hedge fund managers,
portfolio managers, equity analysts, and other professionals at leading financial institutions, along with competitive intelligence, business development, and strategy specialists at major corporations.

Become a bobsguide member to access the following

1. Unrestricted access to bobsguide
2. Send a proposal request
3. Insights delivered daily to your inbox
4. Career development